Patent ID: 7902239
Filing Date: 2011-03-08
Classification: A61P,C07D

Abstract:
1. A method of treating or lessening the severity of a proliferative disorder selected from acute myelogenous leukemia, acute promyelocytic leukemia, or acute lymphocytic leukemia in a patient comprising administering a compound of formula II or II′: or a pharmaceutical composition comprising said compound, in an amount sufficient to treat or lessen the severity of said proliferative disorder in said patient, wherein R R R wherein Ar 2 is an optionally substituted aryl group selected from pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thiophenyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, or an 8-12 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein said aryl group is optionally substituted with y occurrences of Z-R Y ; wherein y is 0-5, Z is a bond or is a C 1 -C 6 alkylidene chain wherein up to two methylene units of Z are optionally replaced by —NR—, —S—, —O—, —CS—, —CO 2 —, —OCO—, —CO—, —COCO—, —CONR—, —NRCO—, —NRCO 2 —, —SO 2 NR—, —NRSO 2 —, —CONRNR—, —NRCONR—, —OCONR—, —NRNR—, —NRSO 2 NR—, —SO—, or —SO 2 —; and each occurrence of R Y is independently R′, halogen, NO 2 , CN, OR′, SR′, N(R′) 2 , NR′COR′, NR′CONR' 2 , NR′CO 2 R′, COR′, CO 2 R′, OCOR′, CON(R′) 2 , OCON(R′) 2 , SOR′, SO 2 R′, SO 2 N(R′) 2 , NR′SO 2 R′, NR′SO 2 N(R′) 2 , COCOR′, or COCH 2 COR′; and each occurrence of R is independently hydrogen or an optionally substituted C